More about

Institute For Clinical And Economic Review

News
December 05, 2023
9 min read
Save

Report: Sotatercept improves clinical outcomes in PAH, but unlikely to be cost-effective

When added to background therapy for pulmonary arterial hypertension, sotatercept improves 6-minute walk distance and WHO functional class vs. placebo, according to an evidence report by the Institute for Clinical and Economic Review.

News
July 31, 2023
2 min read
Save

Despite safety concerns, gene therapies clinically beneficial for sickle cell disease

Evidence suggests two investigational gene therapies provide net health benefits compared with standard approaches for sickle cell disease, according to a revised evidence report from Institute for Clinical and Economic Review.

News
July 21, 2022
2 min read
Save

ICER report: Evidence adequate of beti-cel benefit for patients with beta-thalassemia

Adequate evidence exists to show betibeglogene autotemcel confers a net health benefit vs. standard clinical management for patients with beta-thalassemia, according to a final evidence report by Institute for Clinical and Economic Review.

News
May 13, 2021
3 min read
Save

Report: CAR-T for multiple myeloma clinically beneficial, but value low at current cost

An independent panel unanimously agreed that chimeric antigen receptor T-cell therapy provides clinical benefit superior to the current standard of care for patients with relapsed or refractory multiple myeloma.

News
April 12, 2021
2 min read
Save

CAR-T provides superior efficacy for multiple myeloma at higher cost, report states

Chimeric antigen receptor T-cell therapies demonstrated greater clinical effectiveness than standard care among patients with heavily pretreated multiple myeloma, according to a report by the Institute for Clinical and Economic Review.

News
February 12, 2021
2 min read
Save

Research institute publishes draft report on anti-BCMA therapies for multiple myeloma

The Institute for Clinical and Economic Review published a draft evidence report assessing the comparative clinical effectiveness and value of B-cell maturation antigen-directed therapies for heavily pretreated multiple myeloma.

News
September 24, 2020
1 min read
Save

Institute issues draft scoping plan for review of anti-BCMA therapies for multiple myeloma

The Institute for Clinical and Economic Review has completed a draft scoping document for its planned assessment of chimeric antigen receptor T-cell therapies for the treatment of multiple myeloma.